Heartland Advisors Inc. Purchases New Shares in Core Laboratories Inc. $CLB

Heartland Advisors Inc. acquired a new stake in shares of Core Laboratories Inc. (NYSE:CLB) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,058,311 shares of the oil and gas company’s stock, valued at approximately $12,329,000.

A number of other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Core Laboratories by 10.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,352,329 shares of the oil and gas company’s stock worth $22,705,000 after buying an additional 122,718 shares during the last quarter. Rice Hall James & Associates LLC bought a new position in shares of Core Laboratories in the second quarter valued at approximately $1,184,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Core Laboratories during the second quarter valued at approximately $555,000. UBS Group AG increased its position in shares of Core Laboratories by 32.9% during the fourth quarter. UBS Group AG now owns 412,515 shares of the oil and gas company’s stock valued at $6,613,000 after acquiring an additional 102,151 shares during the last quarter. Finally, Old West Investment Management LLC bought a new stake in Core Laboratories during the second quarter worth $698,000. 97.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Core Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Core Laboratories Price Performance

Shares of NYSE:CLB opened at $12.61 on Friday. The company has a 50 day moving average of $11.52 and a 200 day moving average of $14.46. The stock has a market cap of $578.55 million, a P/E ratio of 22.52, a P/E/G ratio of 2.83 and a beta of 1.03. Core Laboratories Inc. has a 12 month low of $9.79 and a 12 month high of $20.36. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The firm’s revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, sell-side analysts forecast that Core Laboratories Inc. will post 0.56 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Monday, August 10th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories’s dividend payout ratio (DPR) is currently 7.14%.

Insiders Place Their Bets

In related news, CEO Lawrence Bruno acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the transaction, the chief executive officer owned 262,438 shares in the company, valued at $2,829,081.64. This represents a 1.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 1.26% of the stock is owned by corporate insiders.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.